




ISSUE DATE February 6, 2012	EFFECTIVE DATE February 13, 2012	NUMBER *See below
SUBJECT Prior Authorization of Botulinum Toxins – Pharmacy Services		BY  Vincent D. Gordon, Deputy Secretary Office of Medical Assistance Programs

PURPOSE:

The purpose of this bulletin is to:

1. Inform providers that the Department of Public Welfare (Department) will require prior authorization of prescriptions for Botulinum Toxins designated as non-preferred on the Department’s Preferred Drug List (PDL).
2. Issue updated handbook pages that include instructions on how to request prior authorization of prescriptions for Botulinum Toxins that require prior authorization, including the type of medical information needed to evaluate requests for medical necessity.

SCOPE:

This bulletin applies to all licensed pharmacies and prescribers enrolled in the Medical Assistance (MA) Program and providing services in the fee-for-service (FFS) delivery system, including pharmacy services to residents of long term care facilities.

BACKGROUND:

The Department’s Drug Utilization Review (DUR) Board meets semi-annually to review provider prescribing and dispensing practices for efficacy, safety, and quality and to recommend interventions for prescribers and pharmacists through the Department’s Prospective Drug Use Review (ProDUR) and Retrospective Drug Use Review (RetroDUR) programs.

*01-12-13	09-12-13	27-12-13	33-12-13
02-12-13	11-12-13	30-12-13	
03-12-13	14-12-13	31-12-13	
08-12-13	24-12-13	32-12-13	

COMMENTS AND QUESTIONS REGARDING THIS BULLETIN SHOULD BE DIRECTED TO:

The appropriate toll free number for your provider type

Visit the Office of Medical Assistance Programs Web site at
<http://www.dpw.state.pa.us/provider/healthcaremedicalassistance/index.htm>

The Department's Pharmacy and Therapeutics (P&T) Committee meets semi-annually to review published peer-reviewed clinical literature and make recommendations relating to new drugs in therapeutic classes already included in the Preferred Drug List (PDL), changes in the status of drugs on the PDL from preferred to non-preferred and non-preferred to preferred, new quantity limits, and new classes of drugs to be added to or deleted from the PDL. The P&T Committee also recommends new guidelines or modifications to existing guidelines to evaluate requests for prior authorization of prescriptions for medical necessity.

DISCUSSION:

During the September 2, 2011 meeting, the DUR Board recommended that the Department amend the guidelines to determine medical necessity of Botulinum Toxins to address the use of Botox to treat chronic migraine headaches. In October 2010, the Food and Drug Administration (FDA) approved the use of Botox to treat chronic migraine headaches in adults. Revisions also address dosing for available Botulinum Toxin products that were not addressed in the previous listing of quantity limits. Also, during the November 9, 2011 P&T Committee meeting, the P&T Committee recommended adding the Botulinum Toxins class of drugs to the PDL. The guidelines to determine medical necessity of Botulinum Toxins were subject to public review and comment, and subsequently approved for implementation by the Department. The requirements for prior authorization and clinical review guidelines to determine the medical necessity of Botulinum Toxins are included in the attached updated provider handbook pages.

PROCEDURE:

The procedures for prescribers to request prior authorization of Botulinum Toxins is located in SECTION I of the Prior Authorization of Pharmaceutical Services Handbook. The Department will take into account the elements specified in the clinical review guidelines (which are included in the provider handbook pages in the SECTION II chapter related to Botulinum Toxins) in reviewing the prior authorization request to determine medical necessity.

As set forth in 55 Pa. Code §1101.67(a), the procedures described in the handbook pages must be followed to ensure appropriate and timely processing of prior authorization requests for drugs that require prior authorization.

ATTACHMENTS:

[Prior Authorization of Pharmaceutical Services Handbook - Updated pages](#)

SECTION II
Botulinum Toxins